Technical Analysis for AMGN - Amgen Inc.

Grade Last Price % Change Price Change
C 293.54 -1.42% -4.24
AMGN closed down 1.42 percent on Friday, February 7, 2025, on 86 percent of normal volume.
9 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Overbought Stochastic Strength 0.00%
Fell Below 200 DMA Bearish -1.42%
Upper Bollinger Band Walk Strength -1.42%
Multiple of Ten Bearish Other -1.42%
Overbought Stochastic Strength -1.42%
Upper Bollinger Band Touch Strength -1.42%
Crossed Above 200 DMA Bullish -4.64%
Expansion Breakout Bullish Swing Setup -4.64%
Pocket Pivot Bullish Swing Setup -4.64%

   Recent Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Amgen Inc. Description

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB, as well as a strategic alliance with Astellas Pharma Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Medicine Biotechnology Nasdaq 100 Drugs Pharmaceutical Products Clinic Neuroscience Bone Inflammation Monoclonal Antibody Healthcare Providers Dow Jones Component Prostate Cancer Obesity Inflammatory Diseases Wholesale Distributor Dialysis Therapeutic Products Hematology Epidermal Growth Factor Receptor Nephrology Cancer Care Blood Cells Metastases Red Blood Cell Bone Disease Mimics Platelet Recombinant Proteins Necrosis Resistant Prostate Cancer Tumor Necrosis Factor Growth Factors Human Therapeutic Products Tumor Necrosis

Is AMGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 341.7189
52 Week Low 253.3
Average Volume 3,928,375
200-Day Moving Average 302.28
50-Day Moving Average 273.77
20-Day Moving Average 280.15
10-Day Moving Average 289.14
Average True Range 6.77
RSI (14) 61.39
ADX 38.8
+DI 35.68
-DI 10.97
Chandelier Exit (Long, 3 ATRs) 289.18
Chandelier Exit (Short, 3 ATRs) 279.67
Upper Bollinger Bands 302.33
Lower Bollinger Band 257.97
Percent B (%b) 0.8
BandWidth 15.83
MACD Line 6.81
MACD Signal Line 4.40
MACD Histogram 2.4135
Fundamentals Value
Market Cap 157.79 Billion
Num Shares 538 Million
EPS 7.46
Price-to-Earnings (P/E) Ratio 39.35
Price-to-Sales 4.92
Price-to-Book 26.85
PEG Ratio 2.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 304.09
Resistance 3 (R3) 304.94 302.27 302.33
Resistance 2 (R2) 302.27 299.59 301.85 301.74
Resistance 1 (R1) 297.91 297.93 296.58 297.06 301.16
Pivot Point 295.24 295.24 294.58 294.82 295.24
Support 1 (S1) 290.88 292.56 289.55 290.03 285.92
Support 2 (S2) 288.21 290.90 287.79 285.34
Support 3 (S3) 283.85 288.21 284.75
Support 4 (S4) 283.00